A documentation-automation tool for hepatology practices that assembles the fibrosis-stage evidence (VCTE results, FIB-4 trend, biopsy where available) that payers require to approve the newly approved MASH drugs — resmetirom and semaglutide — and auto-generates the prior-authorization packet. AASLD's November 2025 guidance now explicitly endorses identifying F2–F3 treatment candidates with non-invasive tests like VCTE, giving the tool a citable guideline anchor. The tool still treats payer criteria as a moving target: both drugs are accelerated approvals whose final approval awaits long-term outcomes, and payer acceptance of NIT-only staging (versus biopsy) is not yet verified.
The framework reveals a high-value utility tool that leverages a critical timing window created by new FDA approvals and AASLD guidelines. While the operational efficiency is a clear strength, the business model is highly sensitive to the unpredictable alignment between clinical guidelines and payer reimbursement policies.
Strengths4
Weaknesses3
Opportunities3
Threats3
Essential for balancing the internal technical strength of automation against the external threat of payer-driven denial loops or shifting approval statuses. · Generated 2026-10-16 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated